Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

First-Line Osimertinib for EGFR-Mutated Squamous Cell Lung Carcinoma: A Case Report.

Cancer reports (Hoboken, N.J.) - 1 Jul 2025

Matsumura Yugo, Ichihara Seiya, Nii Kaori, Nanjo Kazumasa, Kadota Naoki, Okano Yoshio, Machida Hisanori, Hatakeyama Nobuo, Hino Hiroyuki, Naruse Keishi, Shinohara Tsutomu, Sakiyama Shoji, Tacheuchi Eiji

Abstract excerpt

BACKGROUND: Epidermal growth factor receptor (EGFR) mutations in squamous cell lung carcinoma are rare. EGFR-tyrosine kinase inhibitors are generally less effective for EGFR-mutated squamous cell lung carcinoma. We herein present a case of EGFR-mutated squamous cell lung carcinoma that responded to osimertinib. CASE: A 75-year-old woman with bloody sputum and left back pain was referred to NHO Kochi Hospital. A...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Pyrimidines
Share to Acrylamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aniline Compounds

Share to Carcinoma, Squamous Cell

Share to ErbB Receptors

Share to Indoles

Share to Protein Kinase Inhibitors

Share to Tomography, X-Ray Computed

Source

Open in PubMed Open full text

Identifiers

PMID: 40620186
DOI: 10.1002/cnr2.70273
PMCID: PMC12230503

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

First-Line Osimertinib for EGFR-Mutated Squamous Cell Lung Carcinoma: A Case Report.PMID 40620186Read ↗

Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with EGFR Gene Mutation-Case Report and a Literature Review.Semantic proximity Read ↗

Efficacy of osimertinib for lung squamous cell carcinoma with de novo EGFR T790M-positive: Case report and literature review.Semantic proximity Read ↗

De Novo mutation in Epidermal growth factor receptor (EGFR)-D761Y responding to third generation tyrosine kinase inhibitor Osimertinib: A case report.Semantic proximity Read ↗

An overview of osimertinib as a treatment of non-small cell lung cancer (NSCLC): an update.Semantic proximity Read ↗

Osimertinib for the treatment of non-small cell lung cancer.Semantic proximity Read ↗

Next-generation sequencing clarified why first-line treatment with osimertinib was ineffective in an autopsied case of EGFR-mutated lung squamous cell carcinoma.Semantic proximity Read ↗

First-line osimertinib treatment in patients with lung squamous cell carcinoma harboring active epidermal growth factor receptor mutations.Semantic proximity Read ↗

Osimertinib for Lung Squamous Cell Carcinoma: A Case Report and Literature Review.Semantic proximity Read ↗

Complete response to first-line osimertinib monotherapy in a complex epidermal growth factor receptor mutant ( L833V / H835L ) lung adenocarcinoma patient: a case report.Semantic proximity Read ↗

Real-world osimertinib for EGFR mutation-positive non-small-cell lung cancer with acquired T790M mutation.Semantic proximity Read ↗

Durable response to osimertinib in an advanced lung adenocarcinoma patient with an uncommon EGFR T854A mutation: A case report.Semantic proximity Read ↗

Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.